Xoma | XOMA - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Agenus USD 34.2M 4.61M 2025-12
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Ardelyx USD 114.37M 8.02M 2025-12
aTyr Pharma USD 190K 15.57M 2025-09
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Celldex Therapeutics USD 121K 609K 2025-12
Curis USD 1.14M 8.86M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Incyte USD 1.17B 217.51M 2026-03
MacroGenics USD 31.11M 30.14M 2025-12
Novartis USD 10.07B 184M 2026-03
Novartis USD 10.82B 694M 2025-09
Pfizer USD 11.04B 1.24B 2026-03
Prothena USD 21K 2.39M 2025-12
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Xoma 992K 846K 2024-06